Cancer Targeted Technology develops innovative agents for cancer that accurately detect early and advanced disease, monitor treatment efficacy and improve patient survival and quality of life.


CTT is designing and patenting small molecular weight enzyme inhibitors with unique and unexploited imaging and drug delivery properties. Our first development candidate targets the overexpressed Prostate Specific Membrane Antigen (PSMA) in prostate cancer for both diagnostic and therapeutic applications.


The versatile platform allows expansion into other solid tumor diagnostics and the ability to diagnose and remove circulating tumor cells. Our inhibitors are also efficient drug delivery vehicles for therapy of a large variety of solid tumors.